In the raging arguments over health care insurance, let’s not forget that we have control over much of our own health. (Courtesy photo)

Does glucosamine really help treat arthritis?

In the mid-1990s, patients were coming into my office and telling me their horse or dog did not limp anymore after their veterinarian started them on glucosamine. The patients reported that they felt better after taking it as well — though they hated the big, horse-size pills. Inspired by their remarks, I researched the science behind glucosamine and its relative, chondroitin sulfate. I concluded the data was convincing enough, the supplement could be helpful, and it certainly had no health risk. I then created a glucosamine-rich beverage called “Joint Juice” to solve the problem.

The science behind glucosamine was thin at the time. In the laboratory, glucosamine had been shown to stimulate joint tissue cells to perform several positive actions. First, the glucosamine was a precursor: a building block of the natural lubricant of the joint called hyaluronic acid. The more lubrication, the better the joint worked and felt. Second, glucosamine was a natural anti-inflammatory. Even low levels of anti-inflammatory agents appeared to have positive effects on multiple diseases, not just joint arthritis. Third, glucosamine was a building block for the matrix of articular cartilage. Articular cartilage, which covers of all the bones in a joint, is the surface that becomes damaged from sports or from the disease osteoarthritis. Lastly, glucosamine suppressed some of the degradative enzymes produced in the joint after injury: those enzymes that break down cartilage.

Glucosamine appeared to be the ultimate supplement: one that both relieved symptoms and improved the actual underlying disease. And it did no harm. Early fears that people with shellfish allergies could not take the supplement were solved by sourcing it from vegetables.

However, as with many natural food supplements, the pharmaceutical industry saw glucosamine as a threat.

A major NIH-funded double-blind study — which compared glucosamine and chondroitin sulfate to the leading arthritis drug Celebrex — demonstrated fewer efficacies when all patients were included. In patients with moderate-to-severe arthritis, the supplements showed similar efficacy to the more expensive drug.

Since the lead investigator was an industry consultant, the press release claimed that glucosamine didn’t work. Yet those of us who treat patients didn’t care if glucosamine wasn’t as effective in people with very mild symptoms. We did care that it was as good as Celebrex for the people with moderate-to-severe pain.

Over the years, more studies demonstrated glucosamine’s efficacy. Two recent major studies are worth noting. In one, the cartilage of the joints in 1,593 patients thickened after glucosamine and chondroitin treatment, indicating a reversal of the wear and tear of arthritis. In the other study of 96,000 patients, the relative risk of colon cancer was reduced by 23 percent in the patients who regularly took glucosamine and chondroitin together.

We know that diets, supplements and natural products that reduce inflammation appear to have multiple beneficial effects on our health. Let’s not forget that we have control over much of our own health at our fingertips. And that horses and dogs don’t lie.

Dr. Kevin R. Stone is an orthopedic surgeon at The Stone Clinic and chairman of the Stone Research Foundation in San Francisco.

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Critics blast proposed decades-long lease with gas station on public land

Proposal moves to full Board of Supervisors for vote despite objections

Spin hourly workers ratify first-ever collective bargaining agreement

Union contract awards e-scooter workers with higher pay, additional benefits and more paid-time-off

Prop. 22 puts health of Lyft, Uber drivers at risk

Sneaky wording in ballot initiative would leave gig economy workers in the lurch

After weeks of delay, SFMTA emergency response projects can continue

Board of Supervisors denies five appeals against CEQA exemptions

Attorneys call on city to honor ‘forged’ settlement with Black transit worker

Lawsuit at center of scandal filed by SFMTA employee over alleged discrimination, retaliation

Most Read